Fig. 3

The effect of Bcl-2 silencing on apoptosis during cisplatin treatment in HeLa (a and b) and CaSki (c and d) cells. a Caspase -3/-7 activity, **p < 0.01 vs. sc. seq. ^# p < 0.01 vs. cisplatin and ^$ p < 0.01 vs. Bcl-2 siRNA, n = 4. b PARP cleavage levels, **p < 0.01 vs. sc. seq., ^# p < 0.001 vs. cisplatin and ^$ p < 0.01 vs. Bcl-2 siRNA, n = 3. c Caspase-3/-7, *p < 0.05 vs. sc.seq. and ^# p < 0.05 vs. cisplatin, n = 3. d PARP cleavage, **p < 0.01 vs. sc.seq., ^# p < 0.01 vs. cisplatin and ^$ p < 0.01 vs. Bcl-2 siRNA, n = 3. e PI inclusion (Flow cytometry), PI positive: quadrant A, PI negative: quadrant B *p < 0.05 vs. Cont., Cispl. and Bcl-2 siRNA, n = 3. f Western blot detecting p62 and LC-3 II in HeLa and CaSki cells. Sc. seq. scrambled sequence (control), AU arbitrary units